Cristina Smolenschi
A5012527087- Cancer Genomics and Diagnostics
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Genetic factors in colorectal cancer
- Cancer Treatment and Pharmacology
- Fibroblast Growth Factor Research
- Eosinophilic Disorders and Syndromes
- Cancer Immunotherapy and Biomarkers
- Hepatocellular Carcinoma Treatment and Prognosis
- Renal cell carcinoma treatment
- Gallbladder and Bile Duct Disorders
- Mast cells and histamine
- Gastric Cancer Management and Outcomes
- Cancer Cells and Metastasis
- Colorectal and Anal Carcinomas
- Glioma Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- HER2/EGFR in Cancer Research
- CAR-T cell therapy research
- Virus-based gene therapy research
- Sarcoma Diagnosis and Treatment
- Cancer Research and Treatments
- Neuroendocrine Tumor Research Advances
- Ferroptosis and cancer prognosis
Institut Gustave Roussy
2018-2025
Université Paris-Saclay
2022-2024
Hospital Agioi Anargyroi
2023
Patient-derived organoids (PDOs) are promising tumor avatars that could enable ex vivo drug tests to personalize patients' treatments in the frame of functional precision oncology. However, clinical evidence remains scarce. This study aims evaluate whether PDOs can be implemented practice benefit patients with advanced refractory pancreatic ductal adenocarcinoma (PDAC).
PURPOSE High-risk clonal hematopoiesis (CH) is frequently incidentally found in patients with solid tumors undergoing plasma cell–free DNA sequencing. Here, we aimed to determine if the incidental detection of high-risk CH by liquid biopsy may reveal occult hematologic malignancies tumors. MATERIALS AND METHODS Adult advanced cancers enrolled Gustave Roussy Cancer Profiling study (ClinicalTrials.gov identifier: NCT04932525 ) underwent at least one (FoundationOne Liquid CDx). Molecular...
Abstract Purpose: Understanding resistance to selective FGFR inhibitors is crucial improve the clinical outcomes of patients with FGFR2-driven malignancies. Experimental Design: We analyzed sequential ctDNA, ± whole-exome sequencing, or targeted next-generation sequencing on tissue biopsies from tumors harboring activating FGFR2 alterations progressing pan-FGFR–selective inhibitors, collected in prospective UNLOCK program. FGFR2::BICC1 Ba/F3 and patient-derived xenograft models were used for...
Abstract Background Patient Derived Organoids (PDOs) emerged as the best technology to develop ex vivo tumor avatars. Whether drug testing on PDOs identify efficient therapies will bring clinical utility by improving patient survival remains unclear. To test this hypothesis in frame of trials, PDO faces three main challenges be implemented routine practices: i) generating with a limited amount material; ii) wide panel anti-cancer drugs; and iii) obtaining results within time compatible...
Abstract Background Chemotherapy for metastatic pancreatic adenocarcinoma (PDAC) primarily relies on FOLFIRINOX (LV5FU- irinotecan – Oxaliplatine) and Gemcitabine Nab-Paclitaxel in the first-line setting. However, second-lines remain less well-defined there is limited data regarding third-line treatments. The objective of our study was to determine proportion patients advancing third line chemotherapy, outline various chemotherapy regimens used routine practice evaluate their respective...
Abstract Background: Effective treatment for patients with metastatic cancer is limited, particularly colorectal liver lesions (mCRC), where accessibility to numerous tumours essential favourable clinical outcomes. Oncolytic viruses (OVs) selectively replicate in cells; however, direct targeting of inaccessible limited when using conventional intravenous or intratumoural administration routes. Methods: We conducted a multi-centre, dose-escalation, phase I study vaccinia virus, TG6002, via...
FOLFIRINOX, a primary chemotherapy for metastatic pancreatic cancer, often causes severe toxicity, necessitating hospitalization and dose adjustments. This study aims to identify predictors of FOLFIRINOX focusing on biological, clinical, anthropometric factors. retrospective analyzes adenocarcinoma patients assessing pre-treatment traits. Hospitalizations tolerance during the first month were evaluated using CTCAE v5.0 grading, with early toxicity assessed via factors Anthropometer3DNet...
<p>AEs summarized by relationship to grade.</p>
<p>AEs summarized by relationship to TG6002 and 5-FC.</p>
<p>Adaptive T-cell responses to treatment. function was assessed by ELISpot assay, which showed an IFNγ-release response CEA and TG6002. <b>A,</b> Data expressed as the mean fold change ± SEM SFU of post-treatment samples compared with baseline. <i>n</i> = 6 patients, sample availability–dependent. <b>B,</b> Representative examples from two patients showing BS samples, in triplicate, depicting <b>C</b> <b>D,</b> TCRβ...
<p>Immunophenotyping patient PBMCs</p>
<p>mRNA sequencing of patient PBMCs revealing clustering DEGs involved in immune activation and response pathways to treatment. <b>A,</b> The number upregulated ssDEGs the post-treatment samples relative pretreatment controls for days 2 15 post-infusion. <b>B,</b> Volcano plots three patients that highlight nine commonly expressed (red: downregulated DEGs, blue: black: nonsignificant changes green: specific highlighted ssDEGs). <b>C,</b> Cluster plot...
<p>Trial schema and sampling schedule. <b>A,</b> Trial depicting treatment schedule of two planned cycles IHA TG6002 oral 5-FC. <b>B,</b> Patient blood tissue samples taken at various time points prior to during treatment. Blood were specific for downstream analyses: translational (red), pharmacokinetic (blue), pharmacodynamic (green), neutralizing antibody (purple), biopsies (black). SC, screening; BS, baseline; C, cycle; D, day. (Created with <a...
<div>AbstractPurpose:<p>Effective treatment for patients with metastatic cancer is limited, particularly those colorectal liver lesions, in which accessibility to numerous tumors essential favorable clinical outcomes. Oncolytic viruses (OV) selectively replicate cells; however, direct targeting of inaccessible lesions limited when using conventional intravenous or intratumoral administration routes.</p>Patients and Methods:<p>We conducted a multicenter,...
<p>Detection of TG6002 in patient tumor biopsies. <b>A,</b> Table summary data collated from assays to detect the presence biopsies: qPCR and qRT-PCR viral nucleic acids, plaque assay replication-competent virus (infectious particles per biopsy), IHC determine protein, 5-FU (pg/mg) demonstrate transgene activity. Samples are designated as either positive or negative/below limit detection for each assay. <b>B,</b> Representative examples positively stained cells...